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Breast magnetic resonance imaging (MRI) is exttremely sensitive in the detection of carcinoma, with a sensitivity ranging from 97% to 100%.1 
The specificity is somewhat lower, ranging from 50% 
to 80% as reported previously.2,3 The wide range of 
specificity may be due to the fact that investigators at 
different institutions use a variety of MR imaging techt
niques for acquiring and processing images and possibly 
use different criteria for interpretation. This may also 
be partly due to differing levels of experience with MR 
mammography. Given these limitations when interprett
ing a study, it is important for a radiologist to detert
mine which lesions are suspicious of malignancy and 
need to be biopsied. A standardized terminology has 
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BACkgROuND AND OBJECTIVES: fischer developed a scoring system in 1999 that made identifying malig-
nant lesions much easier for inexperienced radiologists. our study was performed to assess whether this scoring 
system would help beginners to accurately diagnose breast lesions on magnetic resonance (mr) imaging and 
to assess the correlation between the magnetic resonance mammography breast imaging reporting and data 
system (mrm bi-rads) grade and the final diagnosis. 
PATIENTS AND METHODS: the lesion morphology and contrast kinetics of 63 masses in 41 patients were 
evaluated on mri and accorded a mrm bi-rads final assessment category using the fischer scoring system. the 
accuracy was evaluated after the final diagnosis was obtained by tissue sampling and follow-up imaging. 
RESulTS: there were 25 malignant and 30 benign lesions. eight lesions were seen by mri only and we could 
not verify their pathology since we did not have mr-guided biopsy facilities at the time of the study. on mr 
mammography, the proven carcinomatous lesions were characterized as bi-rads category V in 16 (64%), cat-
egory iV in 7 (28%), and category iii in 2 (8%) lesions. benign lesions were graded as category V in 3 (10%), 
category iV in 6 (20%), and category iii in 3 (10%), category ii in 10 (33%) and category i in 8 (27%) lesions. 
the mrm bi-rads category accurately predicted malignancy in 92% and a benign pathology in 70% of the 
lesions. the overlap between the mrm features of chronic inflammatory lesions and carcinomas resulted in a 
lower accuracy in diagnosing benign as compared to malignant lesions. 
CONCluSION: the mrm bi-rads lexicon using the fischer scoring system is useful and has a high predictive 
value, especially for malignant breast lesions, and is easy to apply. overlapping features between benign inflam-
matory and malignant lesions might yield a reduced accuracy in inflammatory pathologies.
been developed to facilitate the interpretation and comt
munication among physicians in the description of mort
phologic findings on mammography. The Breast Imaging 
Reporting and Data System (BItRADS),4 in the form of 
a lexicon, that is widely used in the United States, was 
implemented in our hospital a few years back. It is now 
the standard for reporting conventional xtray mammot
grams and uses descriptors to attach a level of suspicion 
to a lesion and its need for a biopsy. The same lexicon can 
be used for reporting MRI breast.4
The use of morphologic criteria has been shown to 
improve specificity when used to describe breast findings 
on MRI.5,6 For example, smooth or lobulated margins on 
MRI show a 97% to 100% predictive value for benignity, 
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whereas the presence of rim enhancement shows a 79% 
to 92% predictive value for malignancy.5 Despite these 
encouraging results, the value of morphologic criteria to 
describe MRItdetected breast lesions has been limited by 
the lack of a definitive classification scheme. 
In 1999, Fischer et al1 developed a scoring system to 
predict the likelihood of a lesion on MRI as being benign 
or malignant. After the magnetic resonance mammograt
phy (MRM) BItRADS classification system (that mirt
rors the mammographic BItRADS categories) was det
scribed in 2003 by the American College of Radiologists 
(ACR),4 we found that the Fischer scoring system made 
identifying the BItRADS category much easier for inext
perienced radiologists. Our study was performed to ast
sess whether this scoring system would help beginners 
to accurately diagnose breast lesions on MR imaging and 
to assess the correlation between the MRM BItRADS 
grade and the final diagnosis. 
PATIENTS AND METHODS 
In this single center prospective study conducted in a 
breast unit of a general hospital, 41 consecutive cases 
with identified breast lesions on mammography presentt
ing during the period May 2005 to September 2006 
underwent an initial dynamic MR mammography of 
the breast with followtup imaging studies as required up 
to 2 years. The study was conducted using a 1.5T magt
net (GE Excite, South Carolina, USA) and the patients 
constituted part of our initial experience with MR mamt
mography.7 
 The patients included in our study were referred to 
our MR imaging suite with breast lesions for the followt
ing reasons: 
1. Equivocal findings on mammography (n=18), 
2.  Suspicion of local relapse in treated breast cancer 
patients (n=6), 
3.  Search for a primary breast cancer in patients with 
metastatic axillary lymph nodes with suspicious 
lesion on mammography (n=5), 
4.  Local staging of breast cancer (suspicion of multiple 
lesions at standard imaging, dense breasts) (n=5), 
5.  Differentiation between inflammatory benign let
sions vs. inflammatory carcinoma (n=4), 
6.  MRI screening in hightrisk patients with lesion 
suspicious for cancer on mammography (n=3).
We analyzed the morphologic characteristics, ent
hancement pattern and kinetic features of the lesions 
and assigned an appropriate final assessment BItRADS 
category (Table 1). The aim of the study was to assess 
whether the descriptive terminology and final assessment 
categories of the BItRADS lexicon using the Fischer 
scoring system1 corresponded to the final diagnosis of the 
lesions as obtained from histopathological confirmation 
or followtup. 
Patient preparation and positioning 
A 20tgauge intravenous line was inserted at the dorsum 
of the hand before positioning the patient on the table to 
ensure lack of movement between scans. The MRI breast 
was performed with the patient lying in a prone position 
on a platform placed in the MR imager that allows the 
breasts to be in a dependent position. A dedicated 4t
channel breast coil was used. MRI was performed during 
days 6t16 of the menstrual cycle or after stopping hort
mone replacement therapy for 4t6 weeks to avoid false 
positive enhancing lesions during the peak hormonal 
level of the cycle. If the MRI was requested for suspected 
recurrence of malignancy, the MRI study was performed 
6t8 weeks post surgery and at least 9 months (preferably 
12 months) post radiotherapy. 
The protocol 
Axial T1W 3D SPGR volume images (slice thickness 4 
mm, 44 loc per slab, FOV 30, matrix 416×256, NEX 1, 
flip angle 35, bandwidth 41.67) and sagittal fattsaturated 
T2W 2D FRFSE images (slice thickness 5 mm, space 
1 mm, FOV 36, matrix 320×224, NEX 3, TE 85, TR 
5625, echo train length 16, bandwidth 22.73) were obt
tained prior to contrast injection. Either sagittal or axial 
fattsaturated T1W hightresolution 3D SPGR dynamic 
images using vibrant software (slice thickness 4 mm, 
66 loc per slab, matrix 256×160, NEX 1, flip angle 12, 
bandwidth 31.25, ZIP 2 with effective slice thickness of 
2.0 mm) were then obtained with a scan time not exceedt
ing 60 sec per scan. Seven acquisitions were obtained sit
multaneously of both breasts. The first acquisition was 
obtained before contrast was injected and was used as 
a mask and the other 6 acquisitions were obtained folt
lowing contrast injection. The posttcontrast acquisitions 
were finished within 6 minutes. The contrast used was 
0.1 mmol/kg of gadoliniumtDTPA intravenously, usut
ally injected as a bolus using an automatic injector at a 
rate of 2mL/sec, followed by a saline flush. The last set
quence obtained post contrast was a high T1W spatial 
resolution sequence; axial 3D SPGR volume fat satut
rated T1 (slice thickness 4 mm, 44 loc per slab, FOV 
30, matrix 416×256, NEX 1, flip angle 35, bandwidth 
41.67) which was done at almost 7t8 minutes post 
contrast. 
Image interpretation 
The morphology of the lesion was studied on the 3D 
volume T1W images, the fat saturated post contrast 
3D volume T1W images and the fat saturated T2W 
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images and images obtained posttprocessing (maxit
mum intensity projection and maximum slope of signal 
increase). The form, margin and the enhancement patt
tern of the lesions were identified and scored points as 
in Table 1. Evaluation of enhancement kinetics followt
ing contrast agent administration was done on the postt
processed dynamic images using the software function 
tool 2.6.4b3 of GE to measure the signal enhancement 
ratio within the lesions and identify the enhancement 
curves. Since accurate placement of a region of interest 
over the areas of most rapid and intense enhancement 
is critical we used color mapping of the lesions as a 
guide. We followed the quantitative method described 
by Fischer et al1 to study the enhancement curves.
Evaluating the enhancement curves based on 
Fischer’s group 
The evaluation criterion was the peak percentage of 
signal intensity increase within the first 3 minutes after 
contrast material administration relative to the precont
trast signal intensity (initial signal intensity increase). 
The initial signal intensity increase within 3 minutes 
was given a value of less than 50%, 50% to 100% and 
more than 100%. Furthermore, we evaluated the bet
havior of the signal intensity curve from the 3rd to the 
7th minute. A signal intensity increase of more than 
10% within this interval relative to the peak enhancet
ment in the first 3 minutes was defined as “continued 
signal intensity increase” (giving a type I curve). A sigt
nal intensity similar to the peak signal intensity was 
considered as a plateau (giving a type II curve), and a 
decrease of more than 10% was defined as a washout 
(giving a type III curve).
The Fischer scoring system 
In this scoring system, five dynamic contrasttenhanced 
MR features are evaluated. These comprised three mort
phological (shape, margins, enhancement kinetic) and 
two functional features (initial peak of signal intensity 
increase and behaviour of signal intensity curve) cont
stituting a multifactorial protocol in which each critet
rion receives a point value. Each parameter is assigned 
points ranging from 0 to 1 or 0 to 2, with higher points 
for those that are more likely to be associated with mat
lignancy. The sum of all the points defines the degree 
of suspicion of malignancy, with a score 0 representing 
the lowest and 8 the highest degree of suspicion (Table 
1). The points are then assigned a BItRAD category); 
0 and 1 point correspond to category I (negative, no 
abnormal enhancement, enhancing masses or archit
tectural distortion, 2 points corresponds to category 
II (benign findings, for routine follow up), 3 points 
correspond to category III (probably benign requires 
short interval follow up after 6 months), 4 and 5 points 
corresponds to category IV (suspicious abnormality, 
biopsy should be considered) and 6, 7 and 8 points 
correspond to category V (highly suggestive of maligt
nancy, biopsy mandatory) . The appropriate points for 
each lesion were thus given to each feature and were 
recorded in the evaluation score table (Table 1). The 
BItRADS category for the lesion was then identified 
(Figures 1t3). Tissue sampling was performed for cases 
with BItRADS categories III, VI and V.
For the sampled lesions, the BItRADS category 
was then compared with the tissue sampling result (by 
FNAC, core biopsy or lumpectomy/ mastectomy hist
topathology of the tumor). For nontsampled lesions, 
the BItRADS category was determined by clinical folt
low up and repetition of MRI, ultrasonography (US) 
and/or mammography imaging at 12 and 24 months of 
the initial MRI scan. We then evaluated the accuracy of 
Table 1. Criteria for evaluating breast lesions on contrast-enhanced Mr images (the 
evaluation score). 
   Criterion Points 
   1    Shape of contrast-enhanced lesion 
      round, oval, linear, lobular 0 
      Branching, spiculated, stellate 1 
   2    Margin of contrast-enhanced lesion 
       Well-defined 0 
      indistinca/ill-defined 1 
   3    Enhancing pattern of the lesion 
      Homogenous, non-enhancing internal septations 0 
      in-homogenous 1 
      ring enhancement 2 
   4    Initial signal intensity increasea 
      Less than 50% 0 
      50% to 100% 1 
      More than 100% 2 
   5    Signal intensity at 3-6 minutes after contrast injection 
      Steady increase or continuousb 0 
      Plateauc 1 
      Washoutd 2 
ainitial peak signal intensity increase within the first 3 minutes after contrast material administration relative to 
the precontrast signal intensity. bContinued signal intensity increase=signal intensity increase of greater than 10% 
relative to the initial peak signal intensity at 3-8 minutes. cPlateau=deviation of the signal intensity at 3-8 minutes of 
(10%) relative to the initial peak signal intensity. dWashout=signal intensity decrease of greater than 10% relative to 
the initial peak signal intensity at 3-8 minutes. 
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Figure 1. Left breast spiculated mass with ill-defined margin heterogeneous enhancement post contrast with strong initial signal 
increase and post-initial plateau (type ii curve): a) post contrast fat saturated axial T1W image; b) enhancement curve (plateau). 
Spiculated mass (1 point), ill-defined margin (1 point), heterogeneous enhancement post contrast (1 point), strong initial signal 




Figure 2. Left breast rounded mass with well-defined margin showing non-enhancing internal septations with strong initial signal 
increase, and continued signal intensity increase (type 1 curve): a) one minute post contrast fat saturated sagittal image; b) 
enhancement curve. rounded mass (0 point) , well-defined margin (0 point) , non-enhancing internal septations (0 point), strong initial 
signal increase (2 points), continued signal intensity increase (0 point): score 2 points, i.e. MrM Bi-radS category 2. Biopsy proven 
fibroadenoma. 
a b
Figure 3. right breast ill-defined, heterogeneously enhancing oval shaped mass with strong initial signal increase and post-initial 
washout (type iii curve): a) post contrast fat saturated T1W image , b)enhancement curve (washout). ill-defined mass (1 point), 
heterogeneously enhancing (1 point), oval shaped mass (0 point), strong initial signal increase (2 points), post-initial washout (3 
points): score 7 points, i.e. the MrM Bi-radS category is 5. Histopathology proven chronic granulamatous mastitis. 
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BItRADS category using the Fischer scoring system for 
both benign and malignant lesions. 
RESulTS 
Fortytone patients with identified breast lesions on 
mammography and ultrasonography were scanned with 
MRI using the 3D dynamic MRI protocol during May 
2005 to September 2006. The age range of patients was 
25 to 64 years with a mean age of 44.5 years and a met
dian age of 44 years. 
The total number of lesions identified in the 41 pat
tients was 70. Seven of the 70 lesions were seen only on 
MRI and hence were not proven by tissue sampling since 
we had not yet started MRItguided breast biopsy at that 
time and these were excluded from our study. Of the 63 
lesions included in the study, 55 lesions were proved by 
tissue sampling. Twentytfive of the lesions were maligt
nant and 30 were proven to be benign. Eight of the 63 
lesions diagnosed by MRI as benign were not biopsied 
and were followedtup clinically and radiologically at 12 
and 24 months after the initial MRI.
The histopathology of the 25 malignant lesions were 
well differentiated ductal carcinoma in situ in 5, poorly 
differentiated infiltrating ductal carcinomas in 8, wellt
differentiated invasive ductal carcinoma in 6, welltdift
ferentiated infiltrating lobular carcinomas in 5, and one 
welltdifferentiated mucinous carcinoma. Of the total 
breast lesions studied, the diagnostic yield of MRI was 
accurate in detecting malignant lesions in 92% and of 
benign lesions in 70%. Using the final histopathological 
diagnosis of the lesions as the gold standard , the sensit
tivity, specificity, positive and negative predictive values 
of MRI in diagnosing malignant breast lesions were 
96%, 67%, 71% and 95%, respectively. 
Morphological features of 25 pathologically proven 
malignant lesions 
The margins were described as indistinct in 14 (56%) 
(Figure 1) and well circumscribed in 11 (44%). The 
shape was described as spiculated in 9 (36%) (Figure 1), 
round in 8 (32%) branching in 7 (28%) and lobular in 
1 (4%). The enhancement pattern was homogeneous in 
9 (36%), heterogeneous in 7 (28%) (Figure 1), peripht
eral rim in 8 (32%) and septated in 1 (4%). The mean 
size of the 25 carcinomas was 1.6 cm (range, 0.6 to 2.7 
cm) for the homogeneously enhancing masses, 2.7 cm 
(range, 1.0 to 4.4 cm) for the heterogeneously enhancing 
masses, and 2.7 cm (range, 1.1 to 4.3 cm) for the rimtent
hancing masses. Carcinomas less than or equal to 1 cm 
were significantly more common in the homogeneously 
enhancing group than in the heterogeneously or rim ent
hancing groups. Of the 25 carcinomas, 10 (40%) were 
less than 1 cm. 
Morphological features of 30 pathologically proven 
benign lesions 
The margins were described as well circumscribed in 25 
(83%) (Figure 2) and indistinct in 5 (17%) masses. The 
Table 2. The morphological features and kinetics of the proved benign lesions with Bi-radS iV and V categories. 
Category Form Margin Enhancing pattern Initial signal increase Post-initial course 
   Lesion 1 
   Complicated cyst Bi-radS iV Branching Strong Plateau 
   Lesion 2 
   Benign Bi-radS iV Branching inhomogeneous Strong 
   Lesion 3 
   Chronic inflammation Bi-radS iV indistinct inhomogeneous Strong 
   Lesion 4 
   Benign Bi-radS iV indistinct inhomogeneous Strong 
   Lesion 5 
   Organizing inflammation Bi-radS iV Branching inhomogeneous Strong Plateau 
   Lesion 6 
   Scar tissue Bi-radS iV Strong Washout 
   Lesion 7 
   Chronic inflammation Bi-radS V Spiculated indistinct inhomogeneous Strong Plateau 
   Lesion 8 
   granulamatous inflammation Bi-radS V Branching indistinct inhomogeneous Strong Washout 
   Lesion 9 
   granulamatous inflammation Bi-radS V Branching indistinct inhomogeneous Strong Washout 
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shape was described as round in 14 (47%), branching 
in 8 (27%), linear in 4 (13%) and spiculated in 1 (3%). 
The enhancement pattern was homogeneous in 16 
(53%), heterogeneous in 8 (27%), and with nonenhanct
ing internal septations in 4 (13%) (Figure 2). The bet
nign lesions that showed irregular or spiculated margin, 
branching and heterogeneous enhancement were proven 
to be chronic inflammation (Figure 3). The mean size 
was 2.2 cm (range, 0.5 to 4.0 cm) for the homogeneously 
enhancing masses, 3.2 cm (range, 0.3 to 6.0 cm) for the 
heterogeneously enhancing masses and 1.8 cm for the 
septated masses (range, 1.2 to 2.4 cm). 
BI-RADS category of both benign and malignant le-
sions 
The BItRADS classification of the studied 63 lesions 
was as follows: 19 lesions were classified as BItRADS V, 
13 lesions as BItRADS IV, 5 lesions as BItRADS III, 
14 lesions as BItRADS II and 12 lesions as BItRADS 
I. Among the 19 lesions classified as BItRADS V, tissue 
sampling proved the lesions to be malignant in 16 masses 
and chronic inflammation in 3 lesions. Among the 13 let
sions classified as BItRADS IV, the lesions were proven 
by tissue sampling as malignant in 7 lesions, chronic int
flammation in 3, complicated cyst in 1 and benign scar 
tissue in 2. Among the 5 lesions classified as BItRADS 
III, 2 lesions were proven malignant and 3 lesions as bet
nign by tissue sampling. Among the 14 lesions classified 
as BItRADS II, 10 lesions were proven to be benign by 
tissue sampling and 4 lesions were proven benign by 2 
years clinical and radiological follow up. Among the 12 
lesions classified as BItRADS I, 8 lesions were proven 
benign by tissue sampling and 4 lesions were proven bet
nign by 2 years clinical and radiological followtup. Eight 
lesions were not sampled since we did not started MRt
guided breast biopsy at the time of the study. For the bet
nign BItRADS categories (I and II), the impression on 
MR mammography was consistent with the final diagnot
sis of a benign lesions in 100% of the cases. For the mat
lignant MRM BItRADS category (V), this was found 
to be consistent with the final diagnosis of malignancy 
in 84% of the lesions and of MRM BItRADS category 
(IV) in 54% of the lesions. Thirty percent (9 out of 30) of 
benign lesions were diagnosed as malignant or probably 
malignant. No benign lesion was said to be of a category 
above II although in one case diagnosed morphologically 
as fibroadenoma and having BIRADS category III, the 
final diagnosis was invasive ductal carcinoma. The MRM 
BItRADS category was consistent with the histological 
diagnosis of the 25 malignant lesions in 92% and of the 
30 benign lesions in 70% of the masses. The overlapping 
features of chronic inflammatory lesions with carcinomas 
(Table 2, Figure 3) was the reason that the MRM BIt
RADS category was of lower accuracy in diagnosing the 
benign lesions as compared to the malignant lesions.
DISCuSSION 
In our study, we found that the Fischer scoring system1 
and the BItRADS categories worked well for findings 
seen on MR imaging. For the 25 malignant lesions, only 
2 masses were described as probably benign (BItRADS 
category III). Of these one mass showed homogeneous 
enhancement and the other mass showed heterogeneous 
enhancement. Both showed circumscribed margins; one 
was round and the other was lobular in shape. The sizes 
of both masses were small (10 mm and 20 mm). All the 
descriptors used in these 2 cases are associated with a 
benign finding (category II) or probably benign finding 
(category III) in the final assessment categories. The reat
son behind this could be due to multiple factors, includt
ing limited spatial resolution of the dynamic sequences 
used and the overlap of enhancement, both in terms of 
kinetic measurements and morphologic appearances of 
benign and malignant lesions, which precluded comt
plete differentiation of lesions.8t11 If these small masses 
had not been biopsied, a 6tmonth followtup would have 
been performed. As with mammography, if a change 
were noted at that time, biopsy was performed. 
It is becoming increasingly clear that while most int
vestigators have used either enhancement kinetics or let
sion morphology in an attempt to differentiate benign 
enhancing lesions from enhancing breast cancer, an 
integrated interpretation strategy where enhancement 
kinetics data and morphologic feature analysis are used 
together for image interpretation may be superior to the 
use of either method alone.12 Further, since reader varit
ability remains a concern, an imaging lexicon similar to 
the BItRADS lexicon used in conventional xtrays mamt
mography, in which the architectural features are defined 
and illustrated, is needed. 
To characterize a lesion as benign or malignant, one 
should integrate the morphological and the dynamic feat
tures of a lesion. The way to do it varies according to the 
experience of the investigator. For experienced radiolot
gists, the classification of lesions can be done without the 
need of the scoring system suggested by Fischer et al.1 
In this case the classification of the lesion is done based 
on obvious features, e.g. BItRADS V will be given to a 
stellate shape or spiculated border irrespective of the ent
hancement kinetics13,14 and for other lesions with irregut
lar shape and nontsmooth borders and heterogeneous 
architecture the kinetics are referred to; if there is strong 
enhancement and washout it is classified as BItRADS 
V and if intermediate enhancement with plateau or pert
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sistent time course it will then be classified as BItRADS 
IV. Classifying a lesion using this method works very 
well for experienced radiologists, but for inexperienced 
radiologists this might be confusing and might cause 
overt or underestimation of the BItRADS category of 
a lesion. 
Evaluating the enhancement curves can be done with 
either a qualitative11 or quantitative method.1 Kuhl et 
al8 described three types of timetintensity curves: type 
I (steady enhancement), where a persistent increase in 
signal intensity is present beyond 2 minutes after cont
trast agent injection; type II (plateau), where the maxit
mum signal intensity is achieved in the first 2 minutes 
and then remains fairly constant; and type III (washt
out), where the maximum signal intensity is achieved 
in the first 2 minutes and then decreases over time. It 
has been reported that the type I curve is usually seen 
in benign lesions and normal breast parenchyma, the 
type III curve is mostly seen in malignant lesions and 
some fibroadenomas and the type II curve is equivocal 
and seen in some benign lesions and many malignant let
sions.8 The qualitative method needs experience and is 
prone to under or overestimating the curve pattern espet
cially in deciding whether it is a plateau (type II curve) 
or a washtout (type III curve) pattern. The quantitative 
method, however, is easier and gives the inexperienced 
reader more confidence in characterizing the enhancet
ment curve of a lesion.
Nontenhancing internal septations, a descriptor usut
ally associated with fibroadenomas, is a sign that is no 
longer exclusive to benign lesions since recent results of 
a study by Schnall et al11 revealed that 47% of malignant 
lesions were shown to have nonenhancing internal septa. 
In our study, one septated mass that was detected and 
given BItRADS III category proved to be well differentit
ated invasive ductal carcinoma. None of the 25 carcinot
mas was assigned a final assessment of category I or II. 
Also, most of them were assigned a BItRADS category 
IV (28%) or category V (64%), necessitating biopsy even 
by those radiologists who had no experience interpreting 
breast MR images. 
For the 30 benign lesions the overall accuracy was less 
(70%). Three lesions were scored as BItRADS V and 6 
lesions as BItRADS IV. Looking at the pathological diagt
nosis, morphology and the kinetics of these lesions (Table 
2), we found that 5 of these lesions were chronic inflamt
matory lesions and 1 mass was scar tissue. The morphot
logic features of these inflammatory lesions were overlapt
ping with those of the malignant lesions (Figure 3). The 
difficulty in accurately differentiating chronic inflammat
tion from invasive carcinoma was also reported by Rieber 
et al.15 The inclusion of chronic inflammatory lesions in 
our study is the main reason for a reduced accuracy since 
MRI is not a good tool for the differentiation of benign 
from malignancy in such a clinical situation.
In our study, we noticed a higher prevalence of homogt
enous enhancement than heterogeneous and rim enhancet
ment in malignant lesions. We also noticed that the mean 
size of carcinomas showing homogeneous enhancement 
was smaller than the mean size of carcinomas showing 
rim or heterogeneous enhancement. The reason behind 
this could be that 40% of the carcinomas in the current 
series were less than 1 cm in size. Rim enhancement, seen 
in 33% of the ductal carcinomas and in 60% of the lobular 
carcinomas in this series, is considered a suspicious mort
phologic feature.2 The case of mucinous carcinoma in this 
series did not exhibit rim enhancement. 
Nunes et al5 found that none of the malignant masses 
had smooth borders, unlike our study in which 44% of 
the carcinomas had circumscribed borders. Nevertheless, 
most of these lesions had other more worrisome descript
tors, such as heterogeneous or rim enhancement, which 
could be interpreted as malignancy as previously reportt
ed.13 Moreover, mammographically circumscribed masses 
can be malignant, particularly the specific histologic subt
types of medullary, colloid, and papillary carcinoma as 5% 
to 6% of malignant masses have been described as cirt
cumscribed.16 
In our study, we noted that there was a good corret
lation between the MRMtBItRADS final assessment 
category and the eventual diagnosis obtained on histot
pathology or followtup. One weakness of our study was 
that we were forced to exclude 7 lesions from the study 
and analysis as they required MRtguided biopsy that we 
did not perform at the start of the study. It is no doubt 
important to have the facility of performing biopsies 
under MR guidance for lesions not accessible by other 
modalities and in whom a wait and watch policy is not 
advised. 
It is logical that mammographers who are accust
tomed to evaluating breast lesions using BItRADS 
terms on mammography can readily translate those 
skills to MRI. The assignment of a final assessment 
category, as in mammography, indicates to the referring 
physician what appropriate step should be taken next 
and what information should be included in the report. 
 In conclusion, the MRM BItRADS lexicon using the 
Fischer system is easy to apply and very useful and act
curate in characterizing breast lesions. Overlapping MR 
features between some benign lesions like chronic inflamt
mation and malignancy that might reduce the specificity 
need to be interpreted in conjunction with the clinical 
presentation and all other pertinent breast imaging studt
ies, such as mammography and ultrasonography.
original research report Bi-radS in BreaST LeSiOnS
Hematol Oncol Stem Cell Ther 2(3) Third Quarter 2009 hemoncstem.edmgr.com410
1. Fischer U, Vosshenrich r, Probst a, Burch-
hardt H, grabbe e. Breast carcinoma: effect of 
preoperative contrast-enhanced Mr imaging on 
the therapeutic approach. radiol. 1999;213:881-
888. 
2. Lee CH. Problem solving Mr imaging of the 
breast. radiol Clin north am. 2004;42:919-934. 
3. MarBiS Study group. Screening with mag-
netic resonance imaging and mammography of 
a UK population at high familial risk of breast 
cancer: a prospective multicentre cohort study 
(MarBiS). Lancet. 2005;365:1769-1778 . 
4. american College of radiology (aCr): Breast 
imaging reporting and data System (Bi-radS). 
3rd ed. reston, Va: american College of radiol-
ogy; 2003. 
5. nunes LW, Schnall Md, Orel Sg, Hochman 
Mg, Langlotz CP, reynolds Ca, Torosian MH. 
Breast Mr imaging: interpretation model. radiol. 
1997;202:833-841. 
6. nunes LW, Schnall Md, Siegelman eS, Lan-
glotz CP, Orel Sg, Sullivan d, Muenz La, reynolds 
Ca, Torosian MH. diagnostic performance char-
acteristics of architectural features revealed by 
high spatial-resolution Mr imaging of the breast. 
aJr. 1997;169:409-415. 
7. al-Khawari H, Kovacs a, athyal r, al-Manfouhi 
H, Fayaz MS, Madda JP. Breast magnetic reso-
nance imaging: initial experience in Kuwait. Med 
Princ Pract. 2009;18(2):143-8. epub 2009 Feb 10 
8. Kuhl CK, Mielcareck P, Klaschik S, Claudia 
Leutner, eva Wardelmann, gieseke J, Schild HH. 
dynamic breast Mr imaging: are signal intensity 
time course data useful for differential diagnosis 
of enhancing lesions? radiol. 1999;211:101-110. 
9. Kuhl CK. The current status of breast Mr imag-
ing. Part i. Choice of technique, image interpreta-
tion, diagnostic accuracy, and transfer to clinical 
practice. radiol. 2007;244:356-78. 
10. aCr practice guideline for the performance 
of magnetic resonance imaging (Mri) of the 
breast. 2004;517-522. 
11. Schnall Md, Blume J, Bluemke da, deange-
lis ga, deBruhl n, Harms S, Heywang-Köbrun-
ner SH, Hylton n, Kuhl CK, Pisano ed, Causer P, 
Schnitt SJ, Thickman d, Stelling CB, Weatherall 
PT, Lehman C, gatsonis Ca. diagnostic architec-
tural and dynamic features at breast Mr imag-
ing: multicenter study. radiol. 2006;238:42-5 . 
12. Liu PF, debatin JF, Caduff rF, Kacl g, garzoli 
e, Krestin gP. improved diagnostic accuracy in 
dynamic contrast enhanced Mri of the breast by 
combined quantitative and qualitative analysis. 
Br J radiol. 1998;71:501-509. 
13. Tradivon aa, athanasiou a, Thibault F, el 
Khoury C. Breast imaging and reporting data 
system (BiradS): magnetic resonance imaging. 
eJr. 2007 Feb;61(2):212-5. 
14. Kuhl C. dynamic breast magnetic resonance 
imaging. in: elisabeth e Morris, Laura Lieber, edi-
tors. Breast Mri: diagnosis and intervention. 1st 
ed. Springer; 2005. 70-139 p. new York, USa. 
15. rieber a, Tomczak rJ, Mergo PJ, Wenzel V, 
Zeitler H, Brambs HJ. Mri of the breast in the dif-
ferential diagnosis of mastitis versus inflamma-
tory carcinoma and follow-up. J Comput assist 
Tomogr. 1997;21:128-132. 
16. Kopans dB. Breast imaging. 2nd rev. ed. Phil-
adelphia: Lippincott-raven; 1998. page 279. 
REfERENCES
